YESAccepted94% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
Yes. Trial-specific public readouts for NCT04116437 are clearly positive in tone: the Lancet Haematology publication says the results suggest zanubrutinib is a safe and viable option for BTKi-intolerant B-cell malignancies, and an updated sponsor poster says switching to zanubrutinib may provide clinical benefit.
Found Apr 1, 2026, 6:33 PMOutcome date Jan 1, 2023, 12:00 AMReviewed Apr 1, 2026, 6:36 PM
Web Searchpubmed.ncbi.nlm.nih.govJan 1, 2023, 12:00 AM
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous BTK inhibitors in the USA: a phase 2 study - PubMed
PubMed snippet for NCT04116437: “These results suggest that zanubrutinib, a safe and viable treatment… might fill that unmet need” for patients intolerant to ibrutinib or acalabrutinib.
Sponsorbeigenemedical.comSep 14, 2023, 12:00 AM
Updated Safety and Efficacy Results of Zanubrutinib in Patients With B-Cell Malignancies Who Are Intolerant of Ibrutinib and/or Acalabrutinib
Sponsor poster for BGB-3111-215/NCT04116437 says zanubrutinib was well tolerated; disease control was ≥95% in efficacy-evaluable patients; updated outcomes “suggest that… patients… can attain clinical benefit by switching to zanubrutinib.”